Objective We examined associations between ulcer bioburden and ulcer outcomes in neuropathic diabetic foot ulcers (DFUs) that lacked clinical signs of infection. Research Design and Methods Three ...

Chronic wounds, such as diabetic foot ulcers, can present a significant challenge for health care providers. For patients ...

We examined the role of vascular function and inflammation in the development and failure to heal diabetic foot ulcers (DFUs). We followed 104 diabetic patients for a period of 18.4 ± 10.8 months.

Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Mediwound (MDWD – Research Report). The associated price target ...

Now, her company, Siren, has secured $9.5 million, with an $8 million check from lead investor Mölnlycke Health Care to further the development and adoption of its diabetic foot ulcer (DFU ...

This Phase 2, randomized, controlled, multi-center, exploratory open-label study, enrolled 46 subjects (~2:1 randomization) with moderately infected, chronic diabetic foot ulcers in the outpatient ...